Activity in the field of Cell and Gene Therapy (CAGT) has been steadily increasing as the techniques are refined, and patient selection and monitoring are standardized. This white paper builds on the first paper in the CAGT Hot Buttons series, “Introduction to Autologous CAR-T therapy”. Here, we discuss frequently encountered medical hazards of the most widely available autologous Chimeric Antigen Receptor T-cell (CAR-T) therapies in the B cell hematologic malignancy patient population. These complications are cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cardiovascular toxicity, tumor lysis syndrome, infections, hypogammaglobulinemia and cytopenia. We outline considerations for themanagement of these toxicities and we present some considerations from a clinical trial perspective.
CAGT热按钮系列(英)
展开剩余(...)
预读部分内容
预读下一页
微信支付10元后自动下载x
您已支付成功!
提示:请勿删除浏览器缓存。